Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield

After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for a potential approval under a controversial new pathway, the FDA has | Sanofi has gained an FDA expansion for its Type 1 diabetes treatment Tzield. The decision came nearly two months after an original target date under former FDA chief Marty Makary’s controversial Commissioner’s National Priority Voucher (CNPV) program.